drugset / Trial / NCT04705818
Combining Epigenetic And Immune Therapy to Beat Cancer.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.
Timeline
- Start
- 2021-07-23
- Primary completion
- 2024-01-07
- Completion
- 2025-07-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1120 mg | Intravenous |
| Subject | Tazemetostat | Small molecule | 800 mg | Oral |